Bright Arthur

Bright Arthur

Auto-generated profile, based on publicly available information

Bright Arthur

Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2025 in Cancer Discovery
Verified
Journal Article
Open access
NMNicole L. Michmerhuizen
Nicole L. Michmerhuizen
EHEmily B. Heikamp
Emily B. Heikamp
Ilaria IacobucciIlaria Iacobucci
Ilaria Iacobucci
MUMasayuki Umeda
Masayuki Umeda
BABright Arthur
Bright Arthur
CMCharles G Mullighan
Charles G Mullighan
NUP98 fusion oncoproteins (FO) are a hallmark of childhood acute myeloid leukemia. NUP98 FOs drive leukemogenesis through phase-separated condensate formation and maintenance of an active chromatin landscape at stem cell–associated genes in cooperation with epigenetic regulators. In this study, we show that MYST family histone acetyltransferase (HAT) complex proteins, including KAT6A/MOZ, KAT7/HBO1, and the common KAT6A/7 complex subunit BRPF1, associate with NUP98 FOs on chromatin and within condensates. MYST HATs are molecular dependencies in NUP98-rearranged (NUP98-r) leukemia, and genetic inactivation or pharmacologic inhibition of KAT6A and KAT7 impairs NUP98-r cell fitness. KAT6A/7 inhibition decreased global H3K23ac levels, displaced NUP98::HOXA9 from chromatin at the Meis1 locus, and led to myeloid cell differentiation. Additionally, KAT6A/7 inhibition decreased leukemic burden in multiple NUP98-r leukemia xenograft mouse models, synergized with menin inhibitor treatment, and was efficacious in menin inhibitor–resistant cells. In summary, we show that MYST family HATs are therapeutically actionable dependencies in NUP98-r acute myeloid leukemia. Significance: KAT6A and KAT7 associate with NUP98 FOs to drive leukemogenesis. Inhibition of their HAT activity is an effective therapeutic strategy in NUP98-r leukemias, including those resistant to menin inhibition. Moreover, combined KAT6A/7 and menin inhibition is synergistic, supporting clinical translation to improve outcomes for NUP98 FO–driven leukemias.

6 October 2025
Verified
Other
Open access
PDF file
NMNicole L. Michmerhuizen
Nicole L. Michmerhuizen
EHEmily B. Heikamp
Emily B. Heikamp
Ilaria IacobucciIlaria Iacobucci
Ilaria Iacobucci
MUMasayuki Umeda
Masayuki Umeda
BABright Arthur
Bright Arthur
CMCharles G Mullighan
Charles G Mullighan
Supplementary Figure S7 shows that KAT6A/7 and Menin inhibition alter gene expression and remodel chromatin in NUP98-rearranged cells.

6 October 2025
Verified
Other
Open access
NMNicole L. Michmerhuizen
Nicole L. Michmerhuizen
EHEmily B. Heikamp
Emily B. Heikamp
Ilaria IacobucciIlaria Iacobucci
Ilaria Iacobucci
MUMasayuki Umeda
Masayuki Umeda
BABright Arthur
Bright Arthur
CMCharles G Mullighan
Charles G Mullighan
Supplementary Table S1. Exonic mutations/indels in Nup98::Kdm5a;Vav-Cre tumors developing after bone marrow transplant Supplementary Table S2. Exonic mutations/indels in spontaneous Nup98::Kdm5a;Vav-Cre tumors Supplementary Table S3. Enrichment/depletion of gRNAs for in vivo epigentic CRISPR/Cas9 screen Supplementary Table S4. Enrichment/depletion of genes for in vivo epigenetic CRISPR/Cas9 screen Supplementary Table S5. Gene ontology analysis for in vivo epigenetic CRISPR/Cas9 screen Supplementary Table S6. Upregulated gene sets in NUP98::HOXA9 mouse leukemia cells after 72-hour treatment with 2 uM SNDX-5613 + 500 nM PF9363 versus vehicle treatment Supplementary Table S7. Downregulated gene sets in NUP98::HOXA9 mouse leukemia cells after 72-hour treatment with 2 uM SNDX-5613 + 500 nM PF9363 versus vehicle treatment Supplementary Table S8. Statistical analysis of Meis1 ChIPseq peaks Supplementary Table S9. Upregulated gene sets in NUP98::KDM5A AMKL PDX (CPCT0021) after treatment with PF9363 versus vehicle Supplementary Table S10. Downregulated gene sets in NUP98::KDM5A AMKL PDX (CPCT0021) after treatment with PF9363 versus vehicle Supplementary Table S11. Average expression of KAT6A and Menin targets in scRNAseq data Supplementary Table S12. Motif analysis of regions with differentially upregulated accessibility after combination treatment versus vehicle Supplementary Table S13. Motif analysis of regions with differentially downregulated accessibility after combination treatment versus vehicle Supplementary Table S14. Primers used in this study Supplementary Table S15. gRNA sequences used in this study Supplementary Table S16. Antibodies used in this study Supplementary Table S17. Fusion oncoprotein amino acid sequences used in RIME

6 October 2025
Verified
Other
Open access
PDF file
NMNicole L. Michmerhuizen
Nicole L. Michmerhuizen
EHEmily B. Heikamp
Emily B. Heikamp
Ilaria IacobucciIlaria Iacobucci
Ilaria Iacobucci
MUMasayuki Umeda
Masayuki Umeda
BABright Arthur
Bright Arthur
CMCharles G Mullighan
Charles G Mullighan
Supplementary Figure S2 shows that Nup98::Kdm5a;Vav-Cre mice spontaneously develop myeloid disease.


6 October 2025
Verified
Other
Open access
PDF file
NMNicole L. Michmerhuizen
Nicole L. Michmerhuizen
EHEmily B. Heikamp
Emily B. Heikamp
Ilaria IacobucciIlaria Iacobucci
Ilaria Iacobucci
MUMasayuki Umeda
Masayuki Umeda
BABright Arthur
Bright Arthur
CMCharles G Mullighan
Charles G Mullighan
Supplementary Figure S3 shows that NUP98 fusion oncoproteins interact with MYST family histone acetyltransferase complex members.